title: Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.
abstract: Renal cell carcinoma (RCC) ranks the first death rate among the urogenital tumors, whereas its incidence follows the incidences of prostate and bladder cancer. The diagnosis of RCC at early stages allows immediately undertaking appropriate treatment, which significantly increases patients' survival rate. Early and accurate diagnosis avoids inadequate treatment, provides the disease progression forecast, and permits to apply more efficient therapy. Unfortunately, the small renal tumors are usually asymptomatic resulting in the late diagnosis and, therefore, low efficacy of treatment. Thus, sensible and preventive biomarkers are essential for early RCC detection and monitoring of its progression. So far, many attempts were performed aimed at recognizing novel informative kidney tumor biomarkers applicable for early detection of the disease and possessing prognostic and predictive capabilities. This review summarizes recent advances in renal tumor biomarkers recognition, their diagnostic and prognostic values, and clinical feasibility.
authors.affiliation: Department of Cell Signaling, Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991, Moscow, Russia.
authors.forename: Marina O
authors.initials: MO
authors.lastname: Golovastova
authors.affiliation: Institute of Uronephrology and Human Reproductive Health, Sechenov First Moscow State Medical University, 119991, Moscow, Russia.
authors.forename: Dmitry O
authors.initials: DO
authors.lastname: Korolev
authors.affiliation: Anatomic Pathology Department, Sechenov First Moscow State Medical University, 119991, Moscow, Russia.
authors.forename: Larisa V
authors.initials: LV
authors.lastname: Tsoy
authors.affiliation: Anatomic Pathology Department, Sechenov First Moscow State Medical University, 119991, Moscow, Russia.
authors.forename: Vladimir A
authors.initials: VA
authors.lastname: Varshavsky
authors.affiliation: Department of Urology, The Fourth Hospital of Harbin Medical University, Harbin, China.
authors.forename: Wan-Hai
authors.initials: WH
authors.lastname: Xu
authors.affiliation: Institute of Uronephrology and Human Reproductive Health, Sechenov First Moscow State Medical University, 119991, Moscow, Russia.
authors.forename: Andrey Z
authors.initials: AZ
authors.lastname: Vinarov
authors.affiliation: Department of Cell Signaling, Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991, Moscow, Russia.
authors.forename: Evgeni Yu
authors.initials: EY
authors.lastname: Zernii
authors.affiliation: Department of Cell Signaling, Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991, Moscow, Russia.
authors.forename: Pavel P
authors.initials: PP
authors.lastname: Philippov
authors.affiliation: Department of Cell Signaling, Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991, Moscow, Russia. zamyat@belozersky.msu.ru.|Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russia. zamyat@belozersky.msu.ru.
authors.forename: Andrey A
authors.initials: AA
authors.lastname: Zamyatnin
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000737:chemistry* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007680:Kidney Neoplasms / Q000737:chemistry* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D008297:Male; D011379:Prognosis; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
keywords: Cancer-retina antigens; DNA methylation; Epigenetic regulations; Markers; Recoverin; Renal cancer